National Institute on Drug Abuse; Notice of Closed Meetings, 43705-43706 [E9-20633]
Download as PDF
Federal Register / Vol. 74, No. 165 / Thursday, August 27, 2009 / Notices
Advisory Council, 1 Choke Cherry Road,
Room 5–1035, Rockville, Maryland 20857,
Telephone: (240) 276–1692, Fax: (240) 276–
1690, E-mail:
cynthia.graham@samhsa.hhs.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Toian Vaughn,
Committee Management Officer, Substance
Abuse and Mental Health Services
Administration.
[FR Doc. E9–20653 Filed 8–26–09; 8:45 am]
BILLING CODE 4162–20–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center For Scientific Review; Notice of
Closed Meetings
mstockstill on DSKH9S0YB1PROD with NOTICES
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: Center for Scientific
Review Special Emphasis Panel. DKUS
Conflicts.
Date: September 1, 2009.
Time: 10 a.m. to 11 a.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Telephone Conference Call).
Contact Person: Ryan G. Morris, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 4205,
MSC 7814, Bethesda, MD 20892. 301–435–
1501. morrisr@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel. Eclectic
Review.
Date: September 1, 2009.
Time: 12 p.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Telephone Conference Call).
VerDate Nov<24>2008
17:19 Aug 26, 2009
Jkt 217001
Contact Person: Rolf Menzel, PhD,
Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 3196,
MSC 7808, Bethesda, MD 20892. 301–435–
0952. menzelro@csr.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
Name of Committee: Center for Scientific
Review Special Emphasis Panel. UKGD
Member Conflicts.
Date: September 2, 2009.
Time: 2 p.m. to 3:30 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6701
Rockledge Drive, Bethesda, MD 20892.
(Telephone Conference Call).
Contact Person: Bonnie L. Burgess-Beusse,
PhD, Scientific Review Officer, Center for
Scientific Review, National Institutes of
Health, 6701 Rockledge Drive, Room 2182,
MSC 7818, Bethesda, MD 20892. 301–435–
1783. beusseb@mail.nih.gov.
This notice is being published less than 15
days prior to the meeting due to the timing
limitations imposed by the review and
funding cycle.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.306, Comparative Medicine;
93.333, Clinical Research, 93.306, 93.333,
93.337, 93.393–93.396, 93.837–93.844,
93.846–93.878, 93.892, 93.893, National
Institutes of Health, HHS)
Dated: August 17, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–20630 Filed 8–26–09; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Center for Scientific Review;
Cancellation of Meeting
43705
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meeting
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The contract proposals and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the contract
proposals, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel, OutPatient Drug Treatment Research Clinic
(9913).
Date: October 6, 2009.
Time: 9:30 a.m. to 5 p.m.
Agenda: To review and evaluate contract
proposals.
Place: Courtyard by Marriott Rockville,
2500 Research Boulevard, Rockville, MD
20850.
Contact Person: Lyle Furr, Contract Review
Specialist, Office of Extramural Affairs,
National Institute on Drug Abuse, NIH,
DHHS, Room 220, MSC 8401, 6101 Executive
Boulevard, Bethesda, MD 20892–8401, (301)
435–1439, lf33c.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
Dated: August 20, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–20632 Filed 8–26–09; 8:45 am]
BILLING CODE 4140–01–M
Notice is hereby given of the
cancellation of the Center for Scientific
Review Special Emphasis Panel,
October 1, 2009, 8 a.m. to October 2,
2009, 2:00 p.m., Bethesda Marriott, 5151
Pooks Hill Road, Bethesda, MD 20814
which was published in the Federal
Register on August 13, 2009, 74 FR
40823–40824.
The meeting was cancelled due to
administration problems.
Dated: August 20, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–20631 Filed 8–26–09; 8:45 am]
BILLING CODE 4140–01–P
PO 00000
Frm 00042
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse;
Notice of Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), Title 5 U.S.C.,
as amended. The grant applications and
E:\FR\FM\27AUN1.SGM
27AUN1
43706
Federal Register / Vol. 74, No. 165 / Thursday, August 27, 2009 / Notices
mstockstill on DSKH9S0YB1PROD with NOTICES
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Drug Abuse Special Emphasis Panel
Economic Studies of Health Insurance
Coverage on Drug Abuse Treatment.
Date: September 23, 2009.
Time: 1:30 p.m. to 4 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, 6101
Executive Boulevard, Rockville, MD 20852.
(Telephone Conference Call)
Contact Person: Meenaxi Hiremath, PhD,
Health Scientist Administrator, Office of
Extramural Affairs, National Institute on
Drug Abuse, National Institutes of Health,
DHHS, 6101 Executive Blvd., Suite 220, MSC
8401, Bethesda, MD 20892, 301–402–7964,
mh392g@nih.gov.
Name of Committee: National Institute on
Drug Abuse Initial Review Group, Health
Services Research Subcommittee.
Date: October 6–7, 2009.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: The Madison Hotel, 1177 15th St.,
NW., Washington, DC 20005.
Contact Person: Meenaxi Hiremath, PhD,
Health Scientist Administrator, Office of
Extramural Affairs, National Institute on
Drug Abuse, National Institutes of Health,
DHHS, 6101 Executive Blvd., Suite 220, MSC
8401, Bethesda, MD 20892, 301–402–7964,
mh392g@nih.gov.
Name of Committee: National Institute on
Drug Abuse Initial Review Group, Training
and Career Development Subcommittee.
Date: November 3–5, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant
applications.
Place: Ritz Carlton Hotel, 1150 22nd Street,
NW., Washington, DC 20037.
Contact Person: Eliane Lazar-Wesley, PhD,
Health Scientist Administrator, Office of
Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, 6101 Executive
Boulevard, Room 220, MSC 8401, Bethesda,
MD 20892–8401, 301–451–4530,
el6r@nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.279, Drug Abuse and
Addiction Research Programs, National
Institutes of Health, HHS)
VerDate Nov<24>2008
17:19 Aug 26, 2009
Jkt 217001
Dated: August 20, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory
Committee Policy.
[FR Doc. E9–20633 Filed 8–26–09; 8:45 am]
BILLING CODE 4140–01–M
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA–2009–N–0667]
[FDA 09–209–RH–03MOU]
Memorandum of Understanding
Between the Food and Drug
Administration, National Center for
Toxicological Research, and the Air
Force Research Laboratory, 711
Human Performance Wing, Human
Effectiveness Directorate, Biosciences
and Protection Division, for Toxicity of
Nanomaterials
AGENCY:
Food and Drug Administration,
HHS.
ACTION:
Notice.
SUMMARY: The Food and Drug
Administration (FDA) is providing
notice of a memorandum of
understanding (MOU) between FDA and
the Air Force Research Laboratory. This
Memorandum of Understanding (MOU)
between the Food and Drug
Administration, National Center for
Toxicological Research (NCTR), and the
Air Force Research Laboratory, 711
Human Performance Wing, Human
Effectiveness Directorate, Biosciences
and Protection Division, Applied
Biotechnology Branch (711 HPW/RHPB)
(hereinafter referred to as ‘‘the Parties’’),
sets forth the agreement of the Parties to
facilitate information sharing in the area
of toxicogenomic and computational
toxicology research. Through the
exchange of information, the Parties
intend to coordinate research efforts so
as to identify and expedite research and
development of new tools and
technologies that can be implemented
that promote new understanding of the
mechanisms of biological responses to
environmental stressors, including toxic
injury, and to identify biomarkers of
exposure and disease that can be used
to improve and protect human health.
DATES: The agreement became effective
July 28, 2009.
FOR FURTHER INFORMATION CONTACT:
PO 00000
Frm 00043
Fmt 4703
Sfmt 4703
Points of Contact: The following are
Responsible Officers in NCTR and 711
HPW/RHP:
(1) For NCTR: William Slikker, Jr.,
Director, National Center for
Toxicological Research, Food and Drug
Administration, 3900 NCTR Rd.,
Jefferson, AR 72079–9501, phone: 870–
543–7950, fax: 870–543–7576, e-mail:
william.slikker@fda.hhs.gov.
(2) For 711 HPW/RHPB: John J.
Schlager, Chief, Applied Biotechnology
Branch, 2729 R St., Wright-Patterson
AFB, OH 45433–5707, phone: 937–904–
9570, fax: 937–255–1474, e-mail:
john.schlager@wpafb.af.mil.
Points of Contact: The following are
Principal Investigators in NCTR and 711
HPW/RHP:
(1) For NCTR: Syed F. Ali, Senior
Biomedical Research Scientist, National
Center for Toxicological Research, Food
and Drug Administration, 3900 NCTR
Rd., Jefferson, AR 72079–9501, phone:
870–543–7123, fax: 870–543–7745, email: syed.ali@fda.hhs.gov.
(2) For 711 HPW/RHPB: Saber M.
Hussain, Scientist, Group Lead,
Biological Interaction of Nanomaterials,
2729 R St., Wright-Patterson AFB, OH
45433–5707, phone: 937–904–9517, fax:
937–904–9610, e-mail:
saber.hussain@wpafb.af.mil.
Points of Contact: The following are
points of contact for Agreement
Administration in NCTR and 711 HPW:
(1) For NCTR: Thomas J. Flammang,
Deputy Director, Office of Research,
National Center for Toxicological
Research, Food and Drug
Administration, 3900 NCTR Rd.,
Jefferson, AR 72079–9501, phone: 870–
543–7291, fax: 870–543–7576, e-mail:
thomas.flammang@fda.hhs.gov.
(2) For 711 HPW/XPO: James D.
Kearns, Technology Transfer Manager,
2610 Seventh St., Wright-Patterson AFB,
OH 45433–7901, phone: 937–255–3765,
fax: 937–255–7215, e-mail:
jim.kearns@wpafb.af.mil.
In
accordance with 21 CFR 20.108(c),
which states that all written agreements
and MOUs between FDA and others
shall be published in the Federal
Register, the agency is publishing notice
of this MOU.
SUPPLEMENTARY INFORMATION:
Dated: August 18, 2009.
David Horowitz,
Assistant Commissioner for Policy.
BILLING CODE 4160–01–S
E:\FR\FM\27AUN1.SGM
27AUN1
Agencies
[Federal Register Volume 74, Number 165 (Thursday, August 27, 2009)]
[Notices]
[Pages 43705-43706]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E9-20633]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
National Institute on Drug Abuse; Notice of Closed Meetings
Pursuant to section 10(d) of the Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is hereby given of the following
meetings.
The meetings will be closed to the public in accordance with the
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5
U.S.C., as amended. The grant applications and
[[Page 43706]]
the discussions could disclose confidential trade secrets or commercial
property such as patentable material, and personal information
concerning individuals associated with the grant applications, the
disclosure of which would constitute a clearly unwarranted invasion of
personal privacy.
Name of Committee: National Institute on Drug Abuse Special
Emphasis Panel Economic Studies of Health Insurance Coverage on Drug
Abuse Treatment.
Date: September 23, 2009.
Time: 1:30 p.m. to 4 p.m.
Agenda: To review and evaluate grant applications.
Place: National Institutes of Health, 6101 Executive Boulevard,
Rockville, MD 20852. (Telephone Conference Call)
Contact Person: Meenaxi Hiremath, PhD, Health Scientist
Administrator, Office of Extramural Affairs, National Institute on
Drug Abuse, National Institutes of Health, DHHS, 6101 Executive
Blvd., Suite 220, MSC 8401, Bethesda, MD 20892, 301-402-7964,
mh392g@nih.gov.
Name of Committee: National Institute on Drug Abuse Initial
Review Group, Health Services Research Subcommittee.
Date: October 6-7, 2009.
Time: 8:30 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: The Madison Hotel, 1177 15th St., NW., Washington, DC
20005.
Contact Person: Meenaxi Hiremath, PhD, Health Scientist
Administrator, Office of Extramural Affairs, National Institute on
Drug Abuse, National Institutes of Health, DHHS, 6101 Executive
Blvd., Suite 220, MSC 8401, Bethesda, MD 20892, 301-402-7964,
mh392g@nih.gov.
Name of Committee: National Institute on Drug Abuse Initial
Review Group, Training and Career Development Subcommittee.
Date: November 3-5, 2009.
Time: 8 a.m. to 5 p.m.
Agenda: To review and evaluate grant applications.
Place: Ritz Carlton Hotel, 1150 22nd Street, NW., Washington, DC
20037.
Contact Person: Eliane Lazar-Wesley, PhD, Health Scientist
Administrator, Office of Extramural Affairs, National Institute on
Drug Abuse, NIH, DHHS, 6101 Executive Boulevard, Room 220, MSC 8401,
Bethesda, MD 20892-8401, 301-451-4530, el6r@nih.gov.
(Catalogue of Federal Domestic Assistance Program Nos. 93.279, Drug
Abuse and Addiction Research Programs, National Institutes of
Health, HHS)
Dated: August 20, 2009.
Jennifer Spaeth,
Director, Office of Federal Advisory Committee Policy.
[FR Doc. E9-20633 Filed 8-26-09; 8:45 am]
BILLING CODE 4140-01-M